Obesity Management

Singhal discusses the multi-pronged impact of the Commission’s definition of obesity and how it effects clinicians, patients, and the treatment structure itself.

Results from the ATTAIN-MAINTAIN phase 3 study have displayed orforglipron’s efficacy in maintaining weight loss without major safety concerns.

Experts redefine obesity, distinguishing between preclinical and clinical forms, aiming to improve diagnosis and treatment strategies for better health outcomes.

GLP-1 medications are revolutionizing treatment for neurological conditions.

Findings from the CARE feasibility RCT show the safety, feasibility, and likely cost-effectiveness of intentional weight loss before colorectal cancer surgery.

Catch up with major trial results, key clinician insights, and more.

Shagun Bindlish, MD, emphasizes the urgent need to integrate diabetes and obesity care, addressing their shared metabolic roots for better health outcomes.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.

Explore the latest findings on GLP-1 drugs, including their impact on Alzheimer's and promising results for type 1 diabetes treatment.

Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than those with overweight or obesity but without MASLD.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

AASLD 2025 data show mazdutide significantly reduces liver fat, ALT, AST, and insulin resistance in patients with obesity, and MASLD

Eli Lilly and Company’s investigative therapy provided effective and safe weight loss treatment with limited adverse events.

The investigative GLP-1/GCG dual receptor agonist led to a higher proportion of participants achieving HbA1c and body weight improvements from baseline.

A post hoc analysis of the PLIS study has highlighted the comparative effectiveness of glucose levels in achieving prediabetes remission.

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

This episode covers the upcoming glucose monitor Biolinq Shine, the Insulin Icodec FDA resubmission, and the end of Eli Lilly's work in T2D.

Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.

Yale researchers reveal that 17 million U.S. adolescents and young adults qualify for GLP-1RA therapy, highlighting barriers to access and insurance coverage.

Despite the global prevalence of hypercholesterolemia, only 11% of children receive lipid screening, leaving many cases undiagnosed.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.